Currently the most established methods for the biological assessment of disease progression in patients are estimation of regional brain atrophy using structural MRI, PET imaging of glucose metabolism using fluorodeoxyglucose (FDG) and imaging of amyloid deposits (e.g. using [11C]-PIB or [18F]-Florbetapir) as well as invasive CSF sampling to measure tau and amyloid moieties (Langbaum et al., 2013), all of which target specific components of the pathobiological cascade. This evidence concerns the gene MAPT and Brain atrophy.